Bristol-Myers Squibb announced that Erbitux (cetuximab) has gained an expanded indication for the treatment of metastatic head and neck cancer in combination with other chemotherapy. This approval was based on data from a multicenter study conducted in 442 patients with inoperable or widespread disease and who had not received prior chemotherapy. Half were selected to receive either the combination of cetuximab with chemotherapy (cisplatin or carboplatin and 5-fluorouracil) or chemotherapy (cisplatin or carboplatin and 5-fluorouracil) only. Patients receiving the cetuximab with chemotherapy combination lived, on average, 10.1 months compared with 7.4 months for those receiving chemotherapy only.
Erbitux already is FDA-approved for certain types of colon cancer, and for non-metastatic head and neck cancer in combination with radiation therapy (first-line) or as a single agent (following standard treatment).
For more information call (800) 321-1335 or visit www.erbitux.com.